WallStreetZenWallStreetZen

NASDAQ: EPIX
Essa Pharma Inc Stock

Overview
ForecastEarningsDividendOwnership
$6.25-0.15 (-2.34%)
Updated Apr 24, 2024
EPIX Price
$6.25
Fair Value Price
$0.76
Market Cap
$276.49M
52 Week Low
$2.56
52 Week High
$11.67
P/E
-10.59x
P/B
1.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$22M
Beta
0.82
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

EPIX Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EPIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EPIX ($6.25) is overvalued by 719.59% relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EPIX ($6.25) is not significantly undervalued (719.59%) relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EPIX due diligence checks available for Premium users.

Be the first to know about important EPIX news, forecast changes, insider trades & much more!

EPIX News

Valuation

EPIX fair value

Fair Value of EPIX stock based on Discounted Cash Flow (DCF)
Price
$6.25
Fair Value
$0.76
Overvalued by
719.59%
EPIX ($6.25) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EPIX ($6.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EPIX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-10.59x
Industry
15.69x
Market
41.27x

EPIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.97x
Industry
5.86x
EPIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EPIX's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
EPIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$144.5M
Liabilities
$3.8M
Debt to equity
0.03
EPIX's short-term assets ($143.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPIX's short-term assets ($143.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.8M
Investing
$8.2M
Financing
$196.7k
EPIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

EPIX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
EPIX$276.49M-2.34%-10.59x1.97x
RAPT$274.90M-1.25%-2.59x1.87x
NBTX$278.09M+3.33%-5.08x-140.33x
GLUE$274.34M-1.26%-2.08x1.53x
ENTA$273.34M-1.75%-1.97x1.42x
View Top Biotech Stocks

Essa Pharma Stock FAQ

What is Essa Pharma's quote symbol?

(NASDAQ: EPIX) Essa Pharma trades on the NASDAQ under the ticker symbol EPIX. Essa Pharma stock quotes can also be displayed as NASDAQ: EPIX.

If you're new to stock investing, here's how to buy Essa Pharma stock.

What is the 52 week high and low for Essa Pharma (NASDAQ: EPIX)?

(NASDAQ: EPIX) Essa Pharma's 52-week high was $11.67, and its 52-week low was $2.56. It is currently -46.44% from its 52-week high and 144.14% from its 52-week low.

How much is Essa Pharma stock worth today?

(NASDAQ: EPIX) Essa Pharma currently has 44,238,147 outstanding shares. With Essa Pharma stock trading at $6.25 per share, the total value of Essa Pharma stock (market capitalization) is $276.49M.

Essa Pharma stock was originally listed at a price of $88.40 in Mar 13, 2015. If you had invested in Essa Pharma stock at $88.40, your return over the last 9 years would have been -92.93%, for an annualized return of -25.5% (not including any dividends or dividend reinvestments).

How much is Essa Pharma's stock price per share?

(NASDAQ: EPIX) Essa Pharma stock price per share is $6.25 today (as of Apr 24, 2024).

What is Essa Pharma's Market Cap?

(NASDAQ: EPIX) Essa Pharma's market cap is $276.49M, as of Apr 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Essa Pharma's market cap is calculated by multiplying EPIX's current stock price of $6.25 by EPIX's total outstanding shares of 44,238,147.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.